Resistant Hypertension: Novel Insights

Author(s): Guillaume Lamirault*, Mathieu Artifoni, Mélanie Daniel, Nicolas Barber-Chamoux, Nantes University Hospital Working Group on Hypertension

Journal Name: Current Hypertension Reviews

Volume 16 , Issue 1 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Hypertension is the most common chronic disease and the leading risk factor for disability and premature deaths in the world, accounting for more than 9 million deaths annually. Resistant hypertension is a particularly severe form of hypertension. It was described 50 years ago and since then has been a very active field of research. This review aims at summarizing the most recent findings on resistant hypertension.

The recent concepts of apparent- and true-resistant hypertension have stimulated a more precise definition of resistant hypertension taking into account not only the accuracy of blood pressure measurement and pharmacological class of prescribed drugs but also patient adherence to drugs and life-style recommendations.

Recent epidemiological studies have reported a 10% prevalence of resistant hypertension among hypertensive subjects and demonstrated the high cardiovascular risk of these patients. In addition, these studies identified subgroups of patients with even higher morbidity and mortality risk, probably requiring a more aggressive medical management.

In the meantime, guidelines provided more standardized clinical work-up to identify potentially reversible causes for resistant hypertension such as secondary hypertension. The debate is however still ongoing on which would be the optimal method(s) to screen for non-adherence to hypertension therapy, recognized as the major cause for (pseudo)-resistance to treatment.

Recent randomized clinical trials have demonstrated the strong benefit of anti-aldosterone drugs (mostly spironolocatone) as fourth-line therapies in resistant hypertension whereas clinical trials with device-based therapies displayed contrasting results. New trials with improved devices and more carefully selected patients with resistant hypertension are ongoing.

Keywords: Hypertension, resistant hypertension, secondary hypertension, blood pressure measurement, antihypertensive drugs, adherence to therapy, medical devices.

[1]
World Health Organization. A global brief on Hypertension: silent killer, global public health crises (World Health Day 2013). Geneva: WHO 2013. [Online]
[2]
GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Lond Engl 2016; 388(10053): 1659-724.
[3]
GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Lond Engl 2017; 390(10100): 1345-422.
[4]
Van Dyne JR. Iproniazid in the treatment of resistant hypertension. A preliminary report on twenty intractable cases. J Am Geriatr Soc 1960; 8: 454-62.
[5]
Lee RE, Seligmann AW, Clark MA, Borhani NO, Queenan JT, O’Brien ME. Therapeutically refractory hypertension: causative factors, and medical management with chlorothiazide and other agents. Ann Intern Med 1958; 49(5): 1129-37.
[6]
Mansia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007; 16(3): 135-232.
[7]
Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertens Dallas Tex 1979 . 2008; 51(6): 1403-9.
[8]
Grigoryan L, Pavlik VN, Hyman DJ. Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence. J Am Soc Hypertens 2013; 7(6): 471-6.
[9]
Sierra A, de la, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertens Dallas Tex 1979 2011 ; 57(5): 898-902.
[10]
Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens 2016; 10(6): 493-9.
[11]
Banegas JR, Ruilope LM, de la Sierra A, et al. High prevalence of masked uncontrolled hypertension in people with treated hypertension. Eur Heart J 2014; 35(46): 3304-12.
[12]
Galletti F, Barbato A. MINISAL-SIIA Study Group. Prevalence and determinants of resistant hypertension in a sample of patients followed in Italian hypertension centers: results from the MINISAL-SIIA study program. J Hum Hypertens 2016; 30(11): 703-8.
[13]
Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014; 100(11): 855-61.
[14]
Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31(4): 766-74.
[15]
Strauch B, Petrák O, Zelinka T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013; 31(12): 2455-61.
[16]
Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart 2019; 105(2): 98-105.
[17]
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018; 138(17): e484-594.
[18]
Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-104.
[19]
Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association Hypertens Dallas Tex 1979; 72(5) e53-90.2018;.
[20]
Wright JT Jr, Williamson JD, Whelton PK, et al. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373(22): 2103-16.
[21]
Williams B, Mancia G, Spiering W, et al. List of authors/Task Force members. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2018; 36(12): 2284-309.
[22]
Chow CK, Thakkar J, Bennett A, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet 2017; 389(10073): 1035-42.
[23]
Sander GE, Giles TD. Resistant hypertension: concepts and approach to management. Curr Hypertens Rep 2011; 13(5): 347-55.
[24]
Acelajado MC, Pisoni R, Dudenbostel T, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012; 14(1): 7-12.
[25]
Calhoun DA, Booth JN, Oparil S, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertens Dallas Tex 1979. 2014; 63(3): 451-58.
[26]
Modolo R, de Faria AP, Almeida A, Moreno H. Resistant or refractory hypertension: are they different? Curr Hypertens Rep 2014; 16(10): 485.
[27]
Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19(11): 2063-70.
[28]
Dudenbostel T, Acelajado MC, Pisoni R, et al. Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure Hypertens Dallas Tex 1979; 66(1): 126-33. .2015
[29]
Siddiqui M, Judd EK, Oparil S, et al. White-Coat Effect Is Uncommon in Patients With Refractory Hypertension. Hypertens Dallas Tex 1979 2017; 70(3): 645-51.
[30]
Bangalore S, Fayyad R, Laskey R, et al. Treating to New Targets Steering Committee and Investigators. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med 2014; 127(1): 71-81.e1.
[31]
Gijón-Conde T, Graciani A, Banegas JR. Resistant hypertension: demography and clinical characteristics in 6,292 patients in a primary health care setting. Rev Esp Cardiol (Engl Ed) 2014; 67(4): 270-6.
[32]
de Beus E, van der Sande NGC, Bots ML, et al. Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care. BMJ Open 2017; 7(9): e016692
[33]
Sarganas G, Neuhauser HK. Untreated, Uncontrolled, and Apparent Resistant Hypertension: Results of the German Health Examination Survey 2008-2011. J Clin Hypertens (Greenwich) 2016; 18(11): 1146-54.
[34]
Brambilla G, Bombelli M, Seravalle G, et al. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens 2013; 31(10): 2018-24.
[35]
Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125(13): 1635-42.
[36]
Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens 2015; 28(3): 355-61.
[37]
Wei F-F, Zhang Z-Y, Huang Q-F, Staessen JA. Diagnosis and management of resistant hypertension: state of the art. Nat Rev Nephrol 2018; 14(7): 428-41.
[38]
Sim JJ, Bhandari SK, Shi J, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int 2015; 88(3): 622-32.
[39]
Smith SM, Gong Y, Handberg E, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens 2014; 32(3): 635-43.
[40]
Tsioufis C, Kasiakogias A, Kordalis A, et al. Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens 2014; 32(2): 415-22.
[41]
Kumbhani DJ, Steg PG, Cannon CP, et al. REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J 2013; 34(16): 1204-14.
[http://dx.doi.org/10.1093/eurheartj/ehs368] [PMID: 23144048]
[42]
De Nicola L, Gabbai FB, Agarwal R, et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 2013; 61(24): 2461-7.
[43]
Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlöf B, Poulter NR. ASCOT investigators. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens 2011; 29(10): 2004-13.
[44]
Buhnerkempe MG, Botchway A, Nolasco Morales CE, Prakash V, Hedquist L, Flack JM. Predicting the risk of apparent treatment-resistant hypertension: a longitudinal, cohort study in an urban hypertension referral clinic. J Am Soc Hypertens 2018; 12(11): 809-17.
[45]
Salles GF, Cardoso CRL, Pereira VS, Fiszman R, Muxfeldt ES. Prognostic significance of a reduced glomerular filtration rate and interaction with microalbuminuria in resistant hypertension: a cohort study. J Hypertens 2011; 29(10): 2014-23.
[46]
Beus E, de , Bots ML, Zuilen AD, van, et al. Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease. Hypertens Dallas Tex 1979 2015; 66(5): 998-1005.
[47]
Thomas G, Xie D, Chen H-Y, et al. Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study Hypertens Dallas Tex 1979; 67(2): 287-96. .2016
[48]
Viazzi F, Piscitelli P, Ceriello A, et al. AMD‐Annals Study Group. Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus. J Am Heart Assoc 2017; 6(9)e006745
[49]
Egan BM, Kai B, Wagner CS, et al. Low Blood Pressure Is Associated With Greater Risk for Cardiovascular Events in Treated Adults With and Without Apparent Treatment-Resistant Hypertension. J Clin Hypertens (Greenwich) 2017; 19(3): 241-9.
[50]
Siu AL. AMD‐Annals Study Group. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015; 163(10): 778-86.
[51]
O’Brien E, Parati G, Stergiou G, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013; 31(9): 1731-68.
[52]
Gargiulo M, Giovanetti F, Bianchini Massoni C, et al. Bypass to the ankle and foot in the era of endovascular therapy of tibial disease. Results and factors influencing the outcome. J Cardiovasc Surg (Torino) 2014; 55(3): 367-74.
[53]
Staessen JA, Li Y, Hara A, Asayama K, Dolan E, O’Brien E. Blood Pressure Measurement Anno 2016. Am J Hypertens 2017; 30(5): 453-63.
[54]
Boggia J, Li Y, Thijs L, et al. International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) investigators. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 2007; 370(9594): 1219-29.
[55]
Fan H-Q, Li Y, Thijs L, et al. International Database on Ambulatory Blood Pressure In Relation to Cardiovascular Outcomes Investigators. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens 2010; 28(10): 2036-45.
[56]
Staessen JA, O’Brien ET, Amery AK, et al. Ambulatory blood pressure in normotensive and hypertensive subjects: results from an international database. J Hypertens Suppl 1994; 12(7): S1-S12.
[57]
Zhang L, Li Y, Wei F-F, et al. Strategies for classifying patients based on office, home, and ambulatory blood pressure measurement. Hypertens Dallas Tex 1979 2015; 65(6): 1258-65.
[58]
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA . Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertens Dallas Tex 1979; 71(6): e13-115. 2018
[59]
Lloberes P, Lozano L, Sampol G, et al. Obstructive sleep apnoea and 24-h blood pressure in patients with resistant hypertension. J Sleep Res 2010; 19(4): 597-602.
[60]
Muxfeldt ES, Margallo VS, Guimarães GM, Salles GF. Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension. Am J Hypertens 2014; 27(8): 1069-78.
[61]
Harding SM. Prediction formulae for sleep-disordered breathing. Curr Opin Pulm Med 2001; 7(6): 381-5.
[62]
Gordon RD. Primary aldosteronism. J Endocrinol Invest 1995; 18(7): 495-511.
[63]
Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99(6): 1915-42.
[64]
Schmieder RE, Ott C, Schmid A, et al. Adherence to Antihypertensive Medication in Treatment-Resistant Hypertension Undergoing Renal Denervation. J Am Heart Assoc 2016; 5(2)e002343
[65]
Burnier M, Wuerzner G, Struijker-Boudier H, et al. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertens Dallas Tex 1979 2013; 62(2): :218-5.
[66]
Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34(38): 2940-8.
[67]
Clyne W, Mshelia C, McLachlan S, et al. A multinational cross-sectional survey of the management of patient medication adherence by European healthcare professionals. BMJ Open 2016; 6(2)e009610
[68]
Patel P, Gupta PKC, White CMJ, Stanley AG, Williams B, Tomaszewski M. Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens 2016; 30(6): 368-73.
[69]
Burnier M, Santschi V, Favrat B, Brunner HR. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens Suppl 2003; 21(2): S37-42.
[70]
Patel RP, Taylor SD. Factors affecting medication adherence in hypertensive patients. Ann Pharmacother 2002; 36(1): 40-5.
[71]
Gupta P, Patel P, Štrauch B, et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertens Dallas Tex 1979 2017; 69(6): 1113-20.
[72]
Kretchy IA, Owusu-Daaku FT, Danquah SA. Mental health in hypertension: assessing symptoms of anxiety, depression and stress on anti-hypertensive medication adherence. Int J Ment Health Syst 2014; 8: 25.
[73]
Berra E, Azizi M, Capron A, et al. Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. Hypertens Dallas Tex 1979 2016; 68(2): :297-306.
[74]
Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res 2012; 12: 270.
[75]
El Alili M, Vrijens B, Demonceau J, Evers SM, Hiligsmann M. A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol 2016; 82(1): 268-79.
[http://dx.doi.org/10.1111/bcp.12942] [PMID: 27005306]
[76]
Corrêa NB, de Faria AP, Ritter AMV, et al. A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension. J Am Soc Hypertens 2016; 10(6): 510-516.e1.
[http://dx.doi.org/10.1016/j.jash.2016.03.194] [PMID: 27161936]
[77]
Calhoun DA, Jones D, Textor S, et al. American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117(25): e510-26.
[78]
Gupta P, Patel P, Štrauch B, et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertens Dallas Tex 1979 2017; 70(5): 1042-48.
[79]
Smith SM, Gurka MJ, Calhoun DA, Gong Y, Pepine CJ, Cooper-DeHoff RM. Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. Am J Med 2018; 131(12): 1463-1472.e7.
[80]
Graves JW, Bloomfield RL, Buckalew VM Jr. Plasma volume in resistant hypertension: guide to pathophysiology and therapy. Am J Med Sci 1989; 298(6): 361-5.
[81]
Bobrie G, Frank M, Azizi M, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30(8): 1656-64.
[82]
Roush GC, Ernst ME, Kostis JB, Yeasmin S, Sica DA. Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses. J Hypertens 2016; 34(1): 11-9.
[83]
Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertens Dallas Tex 1979 2007; 49(4): 839-45.
[84]
Souza F,de , Muxfeldt E, Fiszman R, et al. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertens Dallas Tex 1979 2010; 55(1): 147-52.
[85]
Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013; 31(10): 2094-102.
[86]
Václavík J, Sedlák R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertens Dallas Tex 57(6): 1069-75..2011;
[87]
Václavík J, Sedlák R, Jarkovský J, Kociánová E, Táborský M. Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). Medicine (Baltimore) 2014; 93(27)e162
[88]
Dahal K, Kunwar S, Rijal J, et al. The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies. Am J Hypertens 2015; 28(11): 1376-85.
[89]
Williams B, MacDonald TM, Morant S, et al. British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386(10008): 2059-68.
[90]
Williams B, MacDonald TM, Morant SV, et al. British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 2018; 6(6): 464-75.
[91]
Oliveras A, Armario P, Clarà A, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens 2016; 34(9): 1863-71.
[92]
Rosa J, Widimský P, Waldauf P, et al. Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One- Year Outcomes of Randomized PRAGUE-15 Study Hypertens Dallas Tex 1979; 67(2): 397-403. .2016
[93]
Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 2015; 17(10): 1057-65.
[94]
Agarwal R, Rossignol P, Garza D, et al. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study. Am J Nephrol 2018; 48(3): 172-80.
[95]
Narkiewicz K, Ratcliffe LEK, Hart EC, et al. Unilateral Carotid Body Resection in Resistant Hypertension: A Safety and Feasibility Trial. JACC Basic Transl Sci 2016; 1(5): 313-24.
[96]
Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA. Symplicity HTN-2 Investigators. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 2012; 126(25): 2976-82.
[97]
Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373(9671): 1275-81.
[98]
Schlaich MP, Schmieder RE, Bakris G, et al. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol 2013; 62(22): 2031-45.
[99]
Bhatt DL, Kandzari DE, O’Neill WW, et al. SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370(15): 1393-401.
[100]
Azizi M, Schmieder RE, Mahfoud F, et al. RADIANCE-HTN Investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018; 391(10137): 2335-45.
[101]
Kandzari DE, Böhm M, Mahfoud F, et al. SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018; 391(10137): 2346-55.
[102]
Townsend RR, Mahfoud F, Kandzari DE, et al. SPYRAL HTN-OFF MED trial investigators*. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 2017; 390(10108): 2160-70.
[103]
Romanov A, Pokushalov E, Ponomarev D, et al. Pulmonary vein isolation with concomitant renal artery denervation is associated with reduction in both arterial blood pressure and atrial fibrillation burden: Data from implantable cardiac monitor. Cardiovasc Ther 2017; 35(4)
[104]
Nammas W, Airaksinen JKE, Paana T, Karjalainen PP. Renal sympathetic denervation for treatment of patients with atrial fibrillation: Reappraisal of the available evidence. Heart Rhythm 2016; 13(12): 2388-94.
[105]
Chen W, Ling Z, Xu Y, et al. Preliminary effects of renal denervation with saline irrigated catheter on cardiac systolic function in patients with heart failure: A Prospective, Randomized, Controlled, Pilot Study. Catheter Cardiovasc Interv 2017; 89(4): E153-61.
[106]
Wallbach M, Lehnig L-Y, Schroer C, et al. Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension. Hypertens Dallas Tex 1979 2016; 67(4): 701-09.
[107]
Spiering W, Williams B, Van der Heyden J, et al. CALM-FIM_EUR investigators. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet 2017; 390(10113): 2655-61.
[108]
Burchell AE, Lobo MD, Sulke N, et al. Arteriovenous anastomosis: is this the way to control hypertension? Hypertens Dallas Tex 1979 2014; 64(1): 6-12.
[109]
Faul J, Schoors D, Brouwers S, et al. Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension. J Vasc Surg 2014; 59(4): 1078-83.
[110]
Lobo MD, Ott C, Sobotka PA, et al. Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension: One-Year Results From the ROX CONTROL HTN Trial. Hypertens Dallas Tex 1979 2017; 70(6): 1099-5.


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Published on: 13 February, 2020
Page: [61 - 72]
Pages: 12
DOI: 10.2174/1573402115666191011111402

Article Metrics

PDF: 60
HTML: 11